Lilly 50 6902 Pill - blue three-sided, 9mm
Generic Name: pirtobrutinib
Pill with imprint Lilly 50 6902 is Blue, Three-sided and has been identified as Jaypirca 50 mg. It is supplied by Eli Lilly and Company.
Jaypirca is used in the treatment of Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma and belongs to the drug class BTK inhibitors. Jaypirca 50 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Lilly 50 6902
Jaypirca
- Generic Name
- pirtobrutinib
- Imprint
- Lilly 50 6902
- Strength
- 50 mg
- Color
- Blue
- Size
- 9.00 mm
- Shape
- Three-sided
- Availability
- Prescription only
- Drug Class
- BTK inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Eli Lilly and Company
- National Drug Code (NDC)
- 00002-6902
See also:
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Velcade
Velcade injection is used to treat multiple myeloma and mantle cell lymphoma. Includes Velcade side ...
Gazyva
Gazyva is used to treat chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) in adults ...
Treanda
Treanda (bendamustine) is used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
More about Jaypirca (pirtobrutinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: BTK inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.